What’s Driving the Surge in Immunome Stock This Monday?
Stock Performance: Immunome Inc. (NASDAQ: IMNM) saw a significant stock increase of 20.87% to $23.65, with trading volume reaching 8.25 million shares, far exceeding its average of 1.50 million.
Clinical Trial Results: The Phase 3 RINGSIDE trial for varegacestat in treating progressing desmoid tumors met its primary endpoint, showing an 84% reduction in disease progression risk and a 56% objective response rate compared to 9% for placebo.
Secondary Endpoints Achieved: The trial also met all key secondary endpoints, demonstrating significant improvements in tumor volume reduction and pain intensity, with varegacestat being well-tolerated.
Future Plans: Immunome plans to submit a New Drug Application to the FDA in Q2 2026, highlighting the trial as the largest conducted for desmoid tumors and emphasizing the potential of varegacestat as a leading treatment option.
Get Free Real-Time Notifications for Any Stock
Analyst Views on IMNM
About IMNM
About the author
IMNM Options Analysis: Put Contract Offers 27.5% YieldBoost
- Put Contract Yield: The $20.00 put contract for IMNM has a current bid of $5.50, and if an investor sells it, they commit to buying shares at $20.00, resulting in a cost basis of $14.50, making it an attractive alternative to the current price of $20.16.
- Expiration Worthless Probability: The odds of the put contract expiring worthless are 75%, and if it does, the premium would yield a 27.5% return on cash commitment, or 13.6% annualized, highlighting the strategy's potential appeal.
- Call Contract Returns: The $22.00 call contract has a current bid of $6.50, and if an investor buys IMNM shares at $20.16 and sells this call, they could achieve a total return of 41.37% if the stock is called away at January 2028 expiration, indicating strong profit potential.
- Call Contract Expiration Worthless Probability: The call contract has a 28% chance of expiring worthless, allowing investors to keep both their shares and the premium collected, with an additional return of 32.24%, or 15.95% annualized, further enhancing the investment's attractiveness.
Insider Buying Update for Friday, December 19: IMNM and S
Immunome Insider Purchase: Immunome's CEO, Clay B. Siegall, bought 46,511 shares of IMNM for $999,986 at $21.50 each, following previous investments totaling $2.16M at an average of $7.53 per share.
SentinelOne Insider Purchase: Director Mark S. Peek of SentinelOne purchased 40,000 shares at $14.89 each for a total of $595,600, while the stock is currently trading lower at $14.61.
Market Performance: Immunome's stock rose approximately 7.9% on Friday, while SentinelOne's stock saw a slight increase of 0.3%.
Disclaimer: The views expressed in the report are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
